Tomer Kariv insider trades: Keros Therapeutics (KROS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Tomer reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | KROS | ↓ Sell | 2,284,612 | $17.75 | $40.6M | By Pontifax (Israel) IV, L.P. | Oct 17, 2025 (2d) |
| Oct 15, 2025 | KROS | ↓ Sell | 1,226,412 | $17.75 | $21.8M | By Pontifax (China) IV, L.P. | Oct 17, 2025 (2d) |
| Oct 15, 2025 | KROS | ↓ Sell | 1,121,045 | $17.75 | $19.9M | By Pontifax (Cayman) IV, L.P. | Oct 17, 2025 (2d) |
| Oct 15, 2025 | KROS | ↓ Sell | 155,262 | $17.75 | $2.8M | By Pontifax Late Stage Fund, L.P. | Oct 17, 2025 (2d) |
| May 13, 2021 | ELOX | ↑ Buy | 5,925,925 | $1.35 | $8.0M | By Pontifax Investment Fund | May 17, 2021 (4d) |
| Nov 17, 2020 | KROS | ↑ Buy | 60,000 | $50.00 | $3.0M | Indirect | Nov 19, 2020 (2d) |
| Apr 13, 2020 | KROS | ↑ Buy | 437,499 | $16.00 | $7.0M | Indirect | Apr 13, 2020 (0d) |
| Nov 11, 2019 | ETNB | ↑ Buy | 250,000 | $16.00 | $4.0M | Indirect | Nov 13, 2019 (2d) |
| Jun 24, 2019 | ELOX | ↑ Buy | 200,000 | $9.00 | $1.8M | By Pontifax Investment Fund | Jun 26, 2019 (2d) |
| Dec 17, 2018 | VBIV | ↑ Buy | 612,997 | $1.40 | $858K | By Pontifax (Israel) IV Limited Partners | Dec 18, 2018 (1d) |
| Dec 17, 2018 | VBIV | ↑ Buy | 331,429 | $1.40 | $464K | By Pontifax (China) IV Limited Partnersh | Dec 18, 2018 (1d) |
| Dec 17, 2018 | VBIV | ↑ Buy | 298,431 | $1.40 | $418K | By Pontifax (Cayman) IV Limited Partners | Dec 18, 2018 (1d) |
| Dec 17, 2018 | VBIV | ↑ Buy | 185,714 | $1.40 | $260K | By Pontifax Late Stage Fund L.P. | Dec 18, 2018 (1d) |
| Oct 23, 2018 | LOGC | ↑ Buy | 420,000 | $10.00 | $4.2M | Indirect | Oct 25, 2018 (2d) |
| Apr 30, 2018 | ELOX | ↑ Buy | 350,000 | $9.75 | $3.4M | By Pontifax Investment Fund | May 1, 2018 (1d) |
| Mar 22, 2018 | ELOX | ↑ Buy | 12,600 | $7.76 | $98K | By Pontifax Investment Fund | Mar 23, 2018 (1d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 707,868 | $0.35 | $248K | By Pontifax (Cayman) II L.P. | Apr 11, 2016 (90d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 533,208 | $0.35 | $187K | By Pontifax (Israel) II L.P. | Apr 11, 2016 (90d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 206,986 | $0.35 | $72K | By Pontifax (Israel) II - Individual Inv | Apr 11, 2016 (90d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 707,868 | $0.35 | $248K | By Pontifax (Cayman) II L.P. | Jan 14, 2016 (2d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 533,208 | $0.35 | $187K | By Pontifax (Israel) II L.P. | Jan 14, 2016 (2d) |
| Jan 12, 2016 | ARNI | ↑ Buy | 206,986 | $0.35 | $72K | By Pontifax (Israel) II - Individual Inv | Jan 14, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KROS insiders
Open-market trades in the last 12 months
About Tomer Kariv's insider trades
Tomer Kariv is a director at Keros Therapeutics (KROS). Since Jan 12, 2016, Tomer has reported 18 open-market purchases worth $34.5M and 4 sales worth $85.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (18 filings), other transactions (5 filings), conversions (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KROS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.